Troxacitabine (brand name Troxatyl) is a nucleoside analogue with anticancer activity. Its use is being studied in patients with refractory lymphoproliferative diseases.[1]

Troxacitabine
Identifiers
  • 4-amino-1-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]pyrimidin-2(1H)-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC8H11N3O4
Molar mass213.193 g·mol−1
3D model (JSmol)
  • O=C1/N=C(/N)\C=C/N1[C@H]2O[C@H](OC2)CO
  • InChI=1S/C8H11N3O4/c9-5-1-2-11(8(13)10-5)6-4-14-7(3-12)15-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7-/m0/s1 checkY
  • Key:RXRGZNYSEHTMHC-BQBZGAKWSA-N checkY
 ☒NcheckY (what is this?)  (verify)

References

edit
  1. ^ Vose JM, Panwalkar A, Belanger R, Coiffier B, Baccarani M, Gregory SA, et al. (January 2007). "A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma". Leukemia & Lymphoma. 48 (1): 39–45. doi:10.1080/10428190600909578. PMID 17325846. S2CID 36220728.